1178 related articles for article (PubMed ID: 16505505)
1. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
2. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
3. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
5. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
7. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
8. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
11. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Hamid Z; Simmons DL
Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
[No Abstract] [Full Text] [Related]
13. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
15. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.
Gerstein HC; Yale JF; Harris SB; Issa M; Stewart JA; Dempsey E
Diabet Med; 2006 Jul; 23(7):736-42. PubMed ID: 16842477
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
18. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L
Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680
[TBL] [Abstract][Full Text] [Related]
20. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]